Article, News
Prescient to advance PTX-100 to phase II for refractory T-cell lymphomas
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study of PTX-100 in patients with advanced malignancies. The study’s focus…